Key result
Edoxaban initiation involves ~72% anticoagulation-naive patients in routine NVAF practice.
Why the study?
The global ETNA-AF programme was initiated to evaluate the effectiveness and safety of edoxaban in patients with non-valvular atrial fibrillation under real-life conditions.
Population
17,769 patients with non-valvular atrial fibrillation from Europe, East Asia, and Japan
Comparison
Antithrombotic therapy before initiation of edoxaban
Design
Observational registry-based cohort study
Follow-up
≥2 years planned
Authors
Loading...
Edoxaban initiation in AF occurs mostly in anticoagulation-naive patients; leaves open whether prior OAC status modifies real-world safety or effectiveness.
Observational (n=17,769)
Yes
In a global real-world registry of patients with atrial fibrillation prescribed edoxaban, nearly three-quarters were anticoagulation-naive, with notable regional variations in prior antithrombotic use.
Caterina et al. (2018) conducted an observational in non-valvular atrial fibrillation (n=17,769). Edoxaban was evaluated on Antithrombotic therapy before initiation of edoxaban. Among 17,769 patients with non-valvular atrial fibrillation prescribed edoxaban in routine practice, 72.3% were anticoagulation-naive and 27.7% had prior oral anticoagulation therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: